论文部分内容阅读
目的 研究重组人白介素 2吸入给药对小鼠克雷伯肺炎感染的保护作用。方法 小鼠以滴鼻感染法进行感染。感染过程中,以鼻腔插管注入法和皮下注射给予小鼠重组人白介素 2。同时另设正常组、阴性对照组、模型组和阳性对照组(庆大霉素组)。观察各组动物肺病理变化,比较平均死亡时间和一周内死亡率,测定支气管肺泡洗涤液中总蛋白、白蛋白含量,碱性磷酸酶、乳酸脱氢酶活力。结果 重组人白介素 2给药组肺病理变化与模型组和阴性对照组相比显著减轻,支气管肺泡洗涤液中总蛋白、白蛋白含量和碱性磷酸酶活力降低。结论 吸入重组人白介素 2缓解感染后肺部病理变化, 为研发重组人白介素 2吸入剂提供了依据。
Objective To study the protective effect of recombinant human interleukin-2 (IL-2) administered to Klebsiella pneumoniae infection in mice. Methods The mice were infected by nasal infection. During infection, mouse recombinant human interleukin 2 was administered by nasal intubation and subcutaneous injection. At the same time, another normal group, negative control group, model group and positive control group (gentamicin group). The pathological changes of lung in each group were observed. The mean death time and the one-week mortality were compared. Total protein, albumin, alkaline phosphatase and lactate dehydrogenase in bronchoalveolar lavage fluid were measured. Results Compared with the model group and the negative control group, the lung pathological changes in the recombinant human interleukin-2 administration group were significantly reduced, and the total protein, albumin content and alkaline phosphatase activity in the bronchoalveolar lavage fluid decreased. Conclusion Recombinant human interleukin-2 (IL-2) can relieve pulmonary pathological changes after infection and provide the basis for the development of recombinant human interleukin-2 inhalation.